HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives
The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month.
You may also be interested in...
Year After Acquisition, Perrigo Waits For US Decision On HRA’s OTC Oral Contraceptive Switch
Wait will be as long as another three months to learn whether HRA will have approval to market OTC a product Perrigo estimates will have $100m in annual sales.
FDA May Ask HRA For Another OTC Birth Control Actual Use Study Due To ‘Improbable Dosing’
With “improbable dosing in approximately 1/3 of participants” in HRA actual use study, FDA asks advisory committees to recommend design changes if it asks firm for another study. FDA asked HRA to explain discrepancies after it began reviewing the firm’s sNDA submitted in June 2022.
PAGB Survey Shows Brits Losing Confidence In Self-Care, Time For UK Government To Act
UK consumers “may be falling back into pre-pandemic behaviours and there is a time-limited opportunity to embed the changes people had embraced during the pandemic,” argues PAGB CEO Michelle Riddalls as the association publishes its latest self-care survey.